risankizumab (Skyrizi)
Jump to navigation
Jump to search
Indications
- moderate to severe plaque psoriasis*
- psoriatic arthritis*
- moderate to severe Crohn's disease
- may be effective for induction & maintenance of ulcerative colitis[3]
* >50% achieve clear skin in 1 year[2]
Dosage
- 90-180 mg SQ every 4-12 weeks
Mechanism of action
- inhibits IL-23
More general terms
References
- ↑ Papp KA, M.D., Blauvelt A, Bukhalo A et al Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med 2017; 376:1551-1560. April 20, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28423301 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1607017
- ↑ 2.0 2.1 Bassett M Risankizumab Resolves Psoriasis in Half of Patients. Superior to ustekinumab for many endpoints in two RCTs. MedPage Today. February 19, 2018 https://www.medpagetoday.com/meetingcoverage/aad/71238?
Gordon K et al Efficacy and safety of risankizumab: Results from two double- blind, placebo- and ustekinumab-controlled, phase 3 trials in moderate-to-severe plaque psoriasis. American Academy of Dermatology (AAD) 2018 - ↑ 3.0 3.1 Louis E, Schreiber S, Panaccione R et al Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA. 2024 Jul 22:e2412414. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39037800 https://jamanetwork.com/journals/jama/fullarticle/2821291